PDCD1 and classic Hodgkin lymphoma: In the pivotal phase 2 trials, overall 1-year PFS rates were comparable with a range between 66.5 and 78.0% for different anti-PD-1 therapy.13–15 Not unexpectedly, outcomes were more favorable for patients who achieved CR.16,17 A retrospective study showed anti-PD-1 therapy led to an ORR of 65% with the 2-year PFS of 42.3% in 64 patients with r/r cHL.18 In the current study, the 3-year PFS rate for responders was 55.1% overall; among patients who achieved CR as their best response, the 3-year PFS rate was 2.5-fold higher than that of patients with PR (i.e., 72.3% and 29.5%, respectively).